Osiris Therapeutics (OSIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2012 | 09-2012 | 06-2012 | 03-2012 | 12-2011 | |
| Sales | 2,935 | 2,151 | 1,626 | 1,137 | 765 |
| Cost of Goods | 880 | 732 | 552 | 387 | 322 |
| Gross Profit | 2,055 | 1,419 | 1,074 | 750 | 443 |
| Operating Expenses | 2,741 | 2,570 | 5,944 | 2,427 | 21,349 |
| Operating Income | 194 | -419 | -4,318 | -1,290 | -20,584 |
| Other Income | -3 | 13 | 21 | 18 | 20 |
| Pre-tax Income | 191 | -406 | -4,297 | -1,272 | -20,564 |
| Income Tax | -10 | 5 | -32 | N/A | -818 |
| Net Income Continuous | 191 | -401 | -4,265 | -1,272 | -19,746 |
| Net Income Discontinuous | -2,805 | -2,513 | N/A | N/A | N/A |
| Net Income | $-2,614 | $-2,914 | $-4,265 | $-1,272 | $5,048 |
| EPS Basic Total Ops | -0.08 | -0.09 | -0.13 | -0.04 | 0.16 |
| EPS Basic Continuous Ops | 0.01 | -0.01 | -0.13 | -0.04 | -0.60 |
| EPS Basic Discontinuous Ops | -0.08 | -0.08 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -0.08 | -0.09 | -0.13 | -0.04 | 0.16 |
| EPS Diluted Continuous Ops | 0.01 | -0.01 | -0.13 | -0.04 | -0.60 |
| EPS Diluted Discontinuous Ops | -0.08 | -0.08 | N/A | N/A | N/A |
| EBITDA(a) | $569 | $-590 | $-4,147 | $-1,113 | $-20,567 |